Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers

Louis S. Cristol, Ishwarlal Jialal, Scott M. Grundy

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The effect of 4 months of low-dose probucol treatment (250 mg/day) on LDL oxidation and on plasma-HDL cholesterol was studied in a prospective, double-blinded, randomized, placebo-controlled trial involving 26 male volunteers. LDL samples isolated at baseline and at 4 months were subjected to in vitro tests of LDL oxidation, involving copper-catalyzed, time-course experiments. For the placebo group, LDL oxidation did not significantly change over the 4-month period. However, in the probucol group, LDL oxidation was significantly inhibited at 4 months, as evidenced by assays measuring conjugated diene formation, lipid peroxide production and altered electrophoretic mobility of oxidized LDL. In fact, in the probucol group the 'lag-phase' of oxidation was prolonged 2.7-fold. Neither probucol nor placebo had a significant effect on plasma HDL-cholesterol: in the probucol group HDL-cholesterol fell from 37.7 ± 7.4 mg/dl to 34.2 ± 8.3 mg/dl (percentage decrease -8.9), while in the placebo group plasma HDL-cholesterol levels were 42.4 ± 8.3 mg/dl and 40.9 ± 7.0 mg/dl at baseline and 4 months (percentage decrease -2.7). Therefore, a low dose of probucol (250 mg/day) given daily seems to afford protection against the oxidative modification of LDL, and does not appear to exert any substantial effect on the plasma lipoprotein profile.

Original languageEnglish (US)
Pages (from-to)11-20
Number of pages10
JournalAtherosclerosis
Volume97
Issue number1
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Probucol
Lipoproteins
Volunteers
HDL Cholesterol
Placebos
Therapeutics
Lipid Peroxides
oxidized low density lipoprotein
Copper
Randomized Controlled Trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers. / Cristol, Louis S.; Jialal, Ishwarlal; Grundy, Scott M.

In: Atherosclerosis, Vol. 97, No. 1, 1992, p. 11-20.

Research output: Contribution to journalArticle

Cristol, Louis S. ; Jialal, Ishwarlal ; Grundy, Scott M. / Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers. In: Atherosclerosis. 1992 ; Vol. 97, No. 1. pp. 11-20.
@article{e21775ab9d2d40d78f3858acb19e1086,
title = "Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers",
abstract = "The effect of 4 months of low-dose probucol treatment (250 mg/day) on LDL oxidation and on plasma-HDL cholesterol was studied in a prospective, double-blinded, randomized, placebo-controlled trial involving 26 male volunteers. LDL samples isolated at baseline and at 4 months were subjected to in vitro tests of LDL oxidation, involving copper-catalyzed, time-course experiments. For the placebo group, LDL oxidation did not significantly change over the 4-month period. However, in the probucol group, LDL oxidation was significantly inhibited at 4 months, as evidenced by assays measuring conjugated diene formation, lipid peroxide production and altered electrophoretic mobility of oxidized LDL. In fact, in the probucol group the 'lag-phase' of oxidation was prolonged 2.7-fold. Neither probucol nor placebo had a significant effect on plasma HDL-cholesterol: in the probucol group HDL-cholesterol fell from 37.7 ± 7.4 mg/dl to 34.2 ± 8.3 mg/dl (percentage decrease -8.9), while in the placebo group plasma HDL-cholesterol levels were 42.4 ± 8.3 mg/dl and 40.9 ± 7.0 mg/dl at baseline and 4 months (percentage decrease -2.7). Therefore, a low dose of probucol (250 mg/day) given daily seems to afford protection against the oxidative modification of LDL, and does not appear to exert any substantial effect on the plasma lipoprotein profile.",
author = "Cristol, {Louis S.} and Ishwarlal Jialal and Grundy, {Scott M.}",
year = "1992",
doi = "10.1016/0021-9150(92)90046-J",
language = "English (US)",
volume = "97",
pages = "11--20",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers

AU - Cristol, Louis S.

AU - Jialal, Ishwarlal

AU - Grundy, Scott M.

PY - 1992

Y1 - 1992

N2 - The effect of 4 months of low-dose probucol treatment (250 mg/day) on LDL oxidation and on plasma-HDL cholesterol was studied in a prospective, double-blinded, randomized, placebo-controlled trial involving 26 male volunteers. LDL samples isolated at baseline and at 4 months were subjected to in vitro tests of LDL oxidation, involving copper-catalyzed, time-course experiments. For the placebo group, LDL oxidation did not significantly change over the 4-month period. However, in the probucol group, LDL oxidation was significantly inhibited at 4 months, as evidenced by assays measuring conjugated diene formation, lipid peroxide production and altered electrophoretic mobility of oxidized LDL. In fact, in the probucol group the 'lag-phase' of oxidation was prolonged 2.7-fold. Neither probucol nor placebo had a significant effect on plasma HDL-cholesterol: in the probucol group HDL-cholesterol fell from 37.7 ± 7.4 mg/dl to 34.2 ± 8.3 mg/dl (percentage decrease -8.9), while in the placebo group plasma HDL-cholesterol levels were 42.4 ± 8.3 mg/dl and 40.9 ± 7.0 mg/dl at baseline and 4 months (percentage decrease -2.7). Therefore, a low dose of probucol (250 mg/day) given daily seems to afford protection against the oxidative modification of LDL, and does not appear to exert any substantial effect on the plasma lipoprotein profile.

AB - The effect of 4 months of low-dose probucol treatment (250 mg/day) on LDL oxidation and on plasma-HDL cholesterol was studied in a prospective, double-blinded, randomized, placebo-controlled trial involving 26 male volunteers. LDL samples isolated at baseline and at 4 months were subjected to in vitro tests of LDL oxidation, involving copper-catalyzed, time-course experiments. For the placebo group, LDL oxidation did not significantly change over the 4-month period. However, in the probucol group, LDL oxidation was significantly inhibited at 4 months, as evidenced by assays measuring conjugated diene formation, lipid peroxide production and altered electrophoretic mobility of oxidized LDL. In fact, in the probucol group the 'lag-phase' of oxidation was prolonged 2.7-fold. Neither probucol nor placebo had a significant effect on plasma HDL-cholesterol: in the probucol group HDL-cholesterol fell from 37.7 ± 7.4 mg/dl to 34.2 ± 8.3 mg/dl (percentage decrease -8.9), while in the placebo group plasma HDL-cholesterol levels were 42.4 ± 8.3 mg/dl and 40.9 ± 7.0 mg/dl at baseline and 4 months (percentage decrease -2.7). Therefore, a low dose of probucol (250 mg/day) given daily seems to afford protection against the oxidative modification of LDL, and does not appear to exert any substantial effect on the plasma lipoprotein profile.

UR - http://www.scopus.com/inward/record.url?scp=0026441110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026441110&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(92)90046-J

DO - 10.1016/0021-9150(92)90046-J

M3 - Article

VL - 97

SP - 11

EP - 20

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -